A Ketogenic Diet Is Acceptable in Women with Ovarian and Endometrial Cancer and Has No Adverse Effects on Blood Lipids: a Randomized, Controlled Trial
A Ketogenic Diet Is Acceptable in Women with Ovarian and Endometrial Cancer and Has No Adverse Effects on Blood Lipids: a Randomized, Controlled Trial
复制标题
DOI：
10.1080/01635581.2019.1645864
复制
发表时间：
2019-07-26
影响因子：
2.9
通讯作者：
Gower, Barbara A.
中科院分区：
文献类型：
--
作者：
Cohen, Caroline W.;Fontaine, Kevin R.;Gower, Barbara A.
生酮饮食（KDs）正在成为包括癌症在内的几种慢性疾病的有效治疗方法。然而，对安全性和依从性的担忧可能会阻止临床医生开KDs的处方。我们假设，与低脂饮食相比，在卵巢癌和子宫内膜癌患者中，KD不会对血脂谱产生负面影响，并且KD受试者会表现出可接受的依从性。受试者被随机分配到KD（70%脂肪，25%蛋白质，5%碳水化合物）或美国癌症协会饮食（ACS；高纤维和低脂肪）。在基线和指定干预12周后测量血脂和酮类。依从性测量包括尿酮在KD和4天的饮食记录。研究人员还检查了饮食记录，以确定一般的消费模式。采用协方差分析和独立t检验评估饮食对血脂和饮食摄入量的差异。相关分析用于估计膳食摄入量与血清分析之间的关联。在12周时，在调整基线值和体重减轻后，饮食组之间的血脂没有显著差异。KD患者的依从性从57%到80%不等。这些发现表明，对于一些癌症患者来说，KDs可能是一种安全可行的治疗方法。
Ketogenic diets (KDs) are emerging as effective therapies for several chronic diseases, including cancer. However, concerns regarding safety and adherence may prevent clinicians from prescribing KDs. We hypothesized that a KD does not negatively affect blood lipid profile compared to a lower-fat diet in ovarian and endometrial cancer patients, and that KD subjects would demonstrate acceptable adherence. Subjects were randomized to either a KD (70% fat, 25% protein, 5% carbohydrate), or the American Cancer Society diet (ACS; high-fiber and lower-fat). Blood lipids and ketones were measured at baseline and after 12 weeks of the assigned intervention. Adherence measures included urinary ketones in the KD and 4 days' diet records. Diet records were also examined to identify general patterns of consumption. Differences between the diets on blood lipids and dietary intake were assessed with Analysis of covariance and independent t-tests. Correlation analyses were used to estimate associations between dietary intake and serum analytes. At 12 weeks, there were no significant differences between diet groups in blood lipids, after adjusting for baseline values and weight loss. Adherence among KD subjects ranged from 57% to 80%. These findings suggest that KDs may be a safe and achievable component of treatment for some cancer patients.